{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T05:22:35Z","timestamp":1784784155621,"version":"3.55.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T00:00:00Z","timestamp":1686528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a second dose of the BioNTech mRNA BNT162b2 vaccine (BNT) as a booster. Studies in the general population suggest an enhanced efficacy of the heterologous (ChAd-BNT) compared to the homologous (BNT-BNT) vaccination regimen. However, an analysis of the efficacy in patient populations with a high risk of severe COVID-19 due to acquired immunodeficiency is still missing. We therefore compared both vaccination regimens in healthy controls, patients with gynecological tumors after chemotherapy, patients on dialysis and patients with rheumatic diseases concerning the humoral and cellular immune response. The humoral and cellular immune response differed substantially in healthy controls compared to patients with acquired immunodeficiency. Overall, the most significant differences between the two immunization regimens were found in neutralizing antibodies. These were always higher after a heterologous immunization. Healthy controls responded well to both vaccination regimens. However, the formation of neutralizing antibodies was more pronounced after a heterologous immunization. Dialysis patients, on the other hand, only developed an adequate humoral and particularly cellular immune response after a heterologous immunization. Tumor and rheumatic patients also - to a weaker extent compared to dialysis patients - benefited from a heterologous immunization. In conclusion, the heterologous COVID-19 vaccination regimens (ChAd-BNT) seem to have an advantage over the homologous vaccination regimens, especially in immunocompromised patients such as patients with end-stage kidney disease treated with hemodialysis.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1187880","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:23:52Z","timestamp":1686543832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients"],"prefix":"10.3389","volume":"14","author":[{"given":"Chang","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sch\u00f6nbrunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann-Georg","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Weinerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"von Baehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saban","family":"Elitok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthold","family":"Hocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mrna-1273 sars-cov-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two rna-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e02438","DOI":"10.1128\/JCM.02438-20","article-title":"A new sars-cov-2 dual-purpose serology test: highly accurate infection tracing and neutralizing antibody response detection","volume":"59","author":"Taylor","year":"2021","journal-title":"J Clin Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"Immunogenicity and reactogenicity of bnt162b2 booster in chadox1-s-primed participants (combivacs): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with chadox1 ncov-19 and bnt162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40249-022-00977-x","article-title":"Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mrna covid-19 vaccine: a systematic review","volume":"11","author":"Lv","year":"2022","journal-title":"Infect Dis Poverty"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04120-y","article-title":"Immunogenicity and efficacy of heterologous chadox1-bnt162b2 vaccination","volume":"600","author":"Pozzetto","year":"2021","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01464-w","article-title":"Immunogenicity and reactogenicity of heterologous chadox1 ncov-19\/mrna vaccination","volume":"27","author":"Schmidt","year":"2021","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01247-7","article-title":"Humoral immunogenicity and tolerability of heterologous chad\/bnt compared with homologous bnt\/bnt and chad\/chad sars-cov-2 vaccination in hemodialysis patients: a multicenter prospective observational study","volume":"35","author":"Haase","year":"2022","journal-title":"J Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2022.05.025","article-title":"T-Cell proliferation assay for the detection of sars-cov-2-specific t-cells","volume":"532","author":"Chu","year":"2022","journal-title":"Clin Chim Acta"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915001","article-title":"Impact of hypertension on long-term humoral and cellular response to sars-cov-2 infection","volume":"13","author":"Chu","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2598-9","article-title":"Sars-cov-2-reactive t cells in healthy donors and patients with covid-19","volume":"587","author":"Braun","year":"2020","journal-title":"Nature"},{"key":"B13","article-title":"Human t lymphocyte activation by pokeweed mitogen induces production of tnf-alpha and gm-csf and helper signaling by il-1 and il-6 results in il-2-dependent t cell growth","volume":"4","author":"Wallays","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/newbio235067a0","article-title":"Activation of t and b lymphocytes by insoluble phytomitogens","volume":"235","author":"Greaves","year":"1972","journal-title":"Nat New Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic sars-cov-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00950208","article-title":"Aspects of immune dysfunction in end-stage renal disease","volume":"3","author":"Kato","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1038\/s41467-021-23173-1","article-title":"Heterologous vaccination regimens with self-amplifying rna and adenoviral covid vaccines induce robust immune responses in mice","volume":"12","author":"Spencer","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1971522","article-title":"To mix or not to mix? a rapid systematic review of heterologous prime-boost covid-19 vaccination","volume":"20","author":"Chiu","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against sars-cov-2 variants after heterologous and homologous chadox1 ncov-19\/bnt162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mrna covid-19 vaccine (com-cov): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002425","article-title":"Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients","volume":"72","author":"Lim","year":"2007","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg330","article-title":"The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing","volume":"18","author":"Anding","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-139X.2007.00283.x","article-title":"Disturbances of acquired immunity in hemodialysis patients","volume":"20","author":"Eleftheriadis","year":"2007","journal-title":"Semin Dial"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020040470","article-title":"Presentation and outcomes of patients with eskd and covid-19","volume":"31","author":"Valeri","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.07.030","article-title":"Outcomes of patients with end-stage kidney disease hospitalized with covid-19","volume":"98","author":"Ng","year":"2020","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03700321","article-title":"Early humoral responses of hemodialysis patients after covid-19 vaccination with bnt162b2","volume":"16","author":"Speer","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current covid-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"Covid-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3390\/vaccines9020147","article-title":"Sars-cov-2 mrna vaccines: immunological mechanism and beyond","volume":"9","author":"Bettini","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against covid-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to sars-cov-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of sars-cov-2 vaccine chadox1 ncov-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of sars-cov-2 mrna vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg9175","article-title":"Mrna vaccination boosts cross-variant neutralizing antibodies elicited by sars-cov-2 infection","volume":"372","author":"Stamatatos","year":"2021","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch towards non-inflammatory, spike-specific igg4 antibodies after repeated sars-cov-2 mrna vaccination","author":"Irrgang","year":"2022","journal-title":"Sci Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1187880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T04:23:54Z","timestamp":1686543834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1187880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,12]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2023.1187880"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1187880","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,12]]},"article-number":"1187880"}}